7QDL の概要
| エントリーDOI | 10.2210/pdb7qdl/pdb |
| 分子名称 | Bromodomain-containing protein 4, (2S,4R)-1-acetyl-4-((5-chloropyrimidin-2-yl)amino)-2-methyl-1,2,3,4-tetrahydroquinoline-6-carboxamide, 1,2-ETHANEDIOL, ... (4 entities in total) |
| 機能のキーワード | inhibitor, histone, epigenetic reader, bromodomain, brd4, bromodomain containing protein 4, antagonist, transcription |
| 由来する生物種 | Homo sapiens (Human) |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 15645.39 |
| 構造登録者 | |
| 主引用文献 | Humphreys, P.G.,Atkinson, S.J.,Bamborough, P.,Bit, R.A.,Chung, C.W.,Craggs, P.D.,Cutler, L.,Davis, R.,Ferrie, A.,Gong, G.,Gordon, L.J.,Gray, M.,Harrison, L.A.,Hayhow, T.G.,Haynes, A.,Henley, N.,Hirst, D.J.,Holyer, I.D.,Lindon, M.J.,Lovatt, C.,Lugo, D.,McCleary, S.,Molnar, J.,Osmani, Q.,Patten, C.,Preston, A.,Rioja, I.,Seal, J.T.,Smithers, N.,Sun, F.,Tang, D.,Taylor, S.,Theodoulou, N.H.,Thomas, C.,Watson, R.J.,Wellaway, C.R.,Zhu, L.,Tomkinson, N.C.O.,Prinjha, R.K. Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate. J.Med.Chem., 65:2262-2287, 2022 Cited by PubMed Abstract: Through regulation of the epigenome, the bromodomain and extra terminal (BET) family of proteins represent important therapeutic targets for the treatment of human disease. Through mimicking the endogenous -acetyl-lysine group and disrupting the protein-protein interaction between histone tails and the bromodomain, several small molecule pan-BET inhibitors have progressed to oncology clinical trials. This work describes the medicinal chemistry strategy and execution to deliver an orally bioavailable tetrahydroquinoline (THQ) pan-BET candidate. Critical to the success of this endeavor was a potency agnostic analysis of a data set of 1999 THQ BET inhibitors within the GSK collection which enabled identification of appropriate lipophilicity space to deliver compounds with a higher probability of desired oral candidate quality properties. SAR knowledge was leveraged via Free-Wilson analysis within this design space to identify a small group of targets which ultimately delivered I-BET567 (), a pan-BET candidate inhibitor that demonstrated efficacy in mouse models of oncology and inflammation. PubMed: 34995458DOI: 10.1021/acs.jmedchem.1c01747 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.67 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
をダウンロード
